Latest Amarantus Biosci Inc (AMBS) Headlines $AMBS
Amarantus BioScience Holdings, Inc. "Transformational Funding Positions Amarantus Heading into 2014 Milestones"
ACCESSWIRE - Mon Mar 10, 12:46PM CDT
New York, NY / ACCESSWIRE / March 10, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Mar 10, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTC:AMBS) (Amarantus or the Company), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced today that it has closed on its previously announced Warrant Solicitation, which the Company elected to increase in size from $3.0M to $3.6M due to oversubscriptions. Concurrently, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. LPC initially purchased 4.0 million shares of Amarantus' common stock at $0.10 per share for $400,000 and has committed to invest, at the sole option of Amarantus, up to an additional $19.6M of equity capital over the term of the purchase agreement. The total gross proceeds to the Company from these two transactions upon closing is $4M.
Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
GlobeNewswire - Thu Mar 06, 6:24AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it entered into an exclusive option agreement with the University of Massachusetts to license the University's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of antibiotic-induced ototoxicity. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for antibiotic-induced ototoxicity and certain other disorders of the ear. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
Amarantus Outlines MANF Research Collaboration Strategy
GlobeNewswire - Mon Mar 03, 11:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today outlined its research collaboration strategy for MANF, the Company's flagship therapeutic protein candidate. Concurrently, the Company expanded the list of select scientific publications for MANF on its website to forty two and highlighted key abstracts focusing on the therapeutic potential for MANF in retinal degeneration from the University of Miami's Bascom Palmer Eye Institute and a new abstract from researchers at the Buck Institute on Aging. A link to this updated scientific MANF information can be found at: http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus BioScience Holdings, Inc. "Q1-2014: The Maturation of Amarantus"
ACCESSWIRE - Mon Feb 24, 10:10AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Mon Feb 24, 7:54AM CST
February 24, 2014 / M2 PRESSWIRE / BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since June 2011 is approximately 902 million shares. Approximately 29.92% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.06. A short squeeze has begun as AMBS is above its SqueezeTrigger Price.
Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs
GlobeNewswire - Mon Feb 24, 6:12AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
CEO Gerald Commissiong of Amarantus to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 19, 6:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
GlobeNewswire - Tue Feb 18, 5:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has entered into definitive agreements with certain existing shareholders whom are accredited investors and participated in the previously announced $3M convertible note and warrant financing. The agreements call for such investors to deliver gross proceeds of $3M to the Company in exchange for the exercise of warrants for 50 million common shares of Amarantus. The solicitation was oversubscribed.
Amarantus to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 8:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 16 Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on February 10-11, 2014 at the Waldorf Astoria in New York City.
Amarantus BioScience Holdings, Inc. - "NFL Players Kick Off Concussion Summit Super Bowl Week Despite Ongoing Litigations"
ACCESSWIRE - Wed Feb 05, 2:04PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International hosted the 2nd Annual #C4CT Concussion Awareness Summit on January 29th, 2014 at the United Nations. The Summit, taking place in the week before Super Bowl XLVIII, brought "scientists, biotech companies and professional athletes together, with the goal of building awareness and advancing scientific and medical opportunities for traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE) and concussions." Forbes Contributor Nicole Fisher details the meeting of the minds that took place between "athletes and scientists to educate one another and discuss the real world of traumatic brain injury, concussions and memory loss." Ms. Fisher's full article is available here: http://www.forbes.com/sites/theapothecary/201...tigations/.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
PR Newswire - Tue Feb 04, 7:30AM CST
ï"
Amarantus BioScience Holdings Inc. "#C4CT @ Super Bowl XLVIII - A day That Will Change the Course of Concussion Management"
ACCESSWIRE - Mon Feb 03, 11:50AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Electronic Cigarette Maker to Partner with Marijuana Company: VaporBrands International Inc. (OTCPINK: VAPR), Amarantus BioScience Holdings Inc. (OTCQB: AMBS) CleanPath Resources Corp. (OTCPINK: CLNP)
ACCESSWIRE - Thu Jan 30, 8:36AM CST
What do you get when you mix an electronic cigarette maker and a provider of medical marijuana?
Bioscience Holdings Inc partners with Boston University School of Medicine to evaluate LymPro in cell cycle dysregulation in Alzheimer's disease
M2 - Thu Jan 30, 3:07AM CST
Biotechnology company Amarantus Bioscience Holdings Inc (Other OTC:AMBS) revealed on Wednesday the launch of research collaboration with Boston University School of Medicine (BUSM).
Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
GlobeNewswire - Wed Jan 29, 6:30AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it is establishing a research collaboration with researchers at Boston University School of Medicine (BUSM). The Company will work together with BUSM Professor of Neurology and Neurosurgery Dr. Robert Stern to evaluate the feasibility of using the LymPro Test (R) as a blood based test to identify patients early in the disease process of the neurodegenerative diseases, chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD).
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Olympusat takes New York Spanish-Language Entertainment Broadcaster, BuenaVision, Nationally
PR Newswire - Tue Jan 28, 8:30AM CST
Olympusat, Inc. has recently signed with BuenaVision, a New York City based broadcaster, to exclusively distribute its high-quality entertainment-based programming, from the Dominican Republic and the Caribbean, to the United States. By adding BuenaVision to its growing suite of Spanish-language networks, Olympusat continues to grow its lineup of 40+ PAY TV Spanish-language channels covering all genres such as movies (contemporary and restored classics), entertainment, country of origin, kids, female and male-oriented, documentaries and more.
ESPN's Andrew Brandt Final Addition to #C4CT Concussion Awareness Summit
GlobeNewswire - Mon Jan 27, 9:37PM CST
Final logistics set for pioneering conference during Super Bowl week featuring NFL Network's Andrea Kremer and more than 15 professional athletes including Jeremy Shockey, Carl Eller and Clinton Portis alongside Dr. Robert Cantu, Dr. Robert Stern and other elite scientists to discuss concussion awareness, diagnostics and treatments in development
Amarantus BioScience Holdings, Inc. "Transformational Funding Positions Amarantus Heading into 2014 Milestones"
ACCESSWIRE - Mon Mar 10, 12:46PM CDT
New York, NY / ACCESSWIRE / March 10, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Mar 10, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTC:AMBS) (Amarantus or the Company), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced today that it has closed on its previously announced Warrant Solicitation, which the Company elected to increase in size from $3.0M to $3.6M due to oversubscriptions. Concurrently, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. LPC initially purchased 4.0 million shares of Amarantus' common stock at $0.10 per share for $400,000 and has committed to invest, at the sole option of Amarantus, up to an additional $19.6M of equity capital over the term of the purchase agreement. The total gross proceeds to the Company from these two transactions upon closing is $4M.
Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
GlobeNewswire - Thu Mar 06, 6:24AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it entered into an exclusive option agreement with the University of Massachusetts to license the University's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of antibiotic-induced ototoxicity. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for antibiotic-induced ototoxicity and certain other disorders of the ear. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
Amarantus Outlines MANF Research Collaboration Strategy
GlobeNewswire - Mon Mar 03, 11:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today outlined its research collaboration strategy for MANF, the Company's flagship therapeutic protein candidate. Concurrently, the Company expanded the list of select scientific publications for MANF on its website to forty two and highlighted key abstracts focusing on the therapeutic potential for MANF in retinal degeneration from the University of Miami's Bascom Palmer Eye Institute and a new abstract from researchers at the Buck Institute on Aging. A link to this updated scientific MANF information can be found at: http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus BioScience Holdings, Inc. "Q1-2014: The Maturation of Amarantus"
ACCESSWIRE - Mon Feb 24, 10:10AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Mon Feb 24, 7:54AM CST
February 24, 2014 / M2 PRESSWIRE / BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since June 2011 is approximately 902 million shares. Approximately 29.92% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.06. A short squeeze has begun as AMBS is above its SqueezeTrigger Price.
Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs
GlobeNewswire - Mon Feb 24, 6:12AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
CEO Gerald Commissiong of Amarantus to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 19, 6:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
GlobeNewswire - Tue Feb 18, 5:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has entered into definitive agreements with certain existing shareholders whom are accredited investors and participated in the previously announced $3M convertible note and warrant financing. The agreements call for such investors to deliver gross proceeds of $3M to the Company in exchange for the exercise of warrants for 50 million common shares of Amarantus. The solicitation was oversubscribed.
Amarantus to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 8:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 16 Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on February 10-11, 2014 at the Waldorf Astoria in New York City.
Amarantus BioScience Holdings, Inc. - "NFL Players Kick Off Concussion Summit Super Bowl Week Despite Ongoing Litigations"
ACCESSWIRE - Wed Feb 05, 2:04PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International hosted the 2nd Annual #C4CT Concussion Awareness Summit on January 29th, 2014 at the United Nations. The Summit, taking place in the week before Super Bowl XLVIII, brought "scientists, biotech companies and professional athletes together, with the goal of building awareness and advancing scientific and medical opportunities for traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE) and concussions." Forbes Contributor Nicole Fisher details the meeting of the minds that took place between "athletes and scientists to educate one another and discuss the real world of traumatic brain injury, concussions and memory loss." Ms. Fisher's full article is available here: http://www.forbes.com/sites/theapothecary/201...tigations/.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
PR Newswire - Tue Feb 04, 7:30AM CST
ï"
Amarantus BioScience Holdings Inc. "#C4CT @ Super Bowl XLVIII - A day That Will Change the Course of Concussion Management"
ACCESSWIRE - Mon Feb 03, 11:50AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Electronic Cigarette Maker to Partner with Marijuana Company: VaporBrands International Inc. (OTCPINK: VAPR), Amarantus BioScience Holdings Inc. (OTCQB: AMBS) CleanPath Resources Corp. (OTCPINK: CLNP)
ACCESSWIRE - Thu Jan 30, 8:36AM CST
What do you get when you mix an electronic cigarette maker and a provider of medical marijuana?
Bioscience Holdings Inc partners with Boston University School of Medicine to evaluate LymPro in cell cycle dysregulation in Alzheimer's disease
M2 - Thu Jan 30, 3:07AM CST
Biotechnology company Amarantus Bioscience Holdings Inc (Other OTC:AMBS) revealed on Wednesday the launch of research collaboration with Boston University School of Medicine (BUSM).
Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
GlobeNewswire - Wed Jan 29, 6:30AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it is establishing a research collaboration with researchers at Boston University School of Medicine (BUSM). The Company will work together with BUSM Professor of Neurology and Neurosurgery Dr. Robert Stern to evaluate the feasibility of using the LymPro Test (R) as a blood based test to identify patients early in the disease process of the neurodegenerative diseases, chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD).
Latest Retinitis Pigmentosa (Retinitis) Pipeline Review
M2 - Tue Jan 28, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjq6dr/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013" report to their offering. 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Scope - A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis). - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sangamo BioSciences, Inc. - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - Amarantus Bioscience Holdings, Inc. - ProRetina Therapeutics, S.L - RetroSense Therapeutics, LLC - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/cjq6dr/retinitis
Olympusat takes New York Spanish-Language Entertainment Broadcaster, BuenaVision, Nationally
PR Newswire - Tue Jan 28, 8:30AM CST
Olympusat, Inc. has recently signed with BuenaVision, a New York City based broadcaster, to exclusively distribute its high-quality entertainment-based programming, from the Dominican Republic and the Caribbean, to the United States. By adding BuenaVision to its growing suite of Spanish-language networks, Olympusat continues to grow its lineup of 40+ PAY TV Spanish-language channels covering all genres such as movies (contemporary and restored classics), entertainment, country of origin, kids, female and male-oriented, documentaries and more.
ESPN's Andrew Brandt Final Addition to #C4CT Concussion Awareness Summit
GlobeNewswire - Mon Jan 27, 9:37PM CST
Final logistics set for pioneering conference during Super Bowl week featuring NFL Network's Andrea Kremer and more than 15 professional athletes including Jeremy Shockey, Carl Eller and Clinton Portis alongside Dr. Robert Cantu, Dr. Robert Stern and other elite scientists to discuss concussion awareness, diagnostics and treatments in development
